|
|
|
| NCBP1 Associated with Immune Infiltration in Breast Cancer as a Diagnosis and Prognostic Biomarker |
| XUAN Shu, CHU Ruo-wen |
| Liaoning Normal University, Dalian Liaoning 116029, China |
|
|
|
|
Abstract Objective: This research aims to investigate the clinical significance of NCBP1 associated with breast cancer. Methods: In this study, we compared the expression of NCBP1 in breast cancer and normal tissues. The prognostic potential of NCBP1 was evaluated by Kaplan-Meier(KM) plotter. Then the prognostic value was further confirmed by cox hazard regression analysis and nomogram model. The diagnostic value of NCBP1 was evaluated by ROC curve. Later the association of NCBP1 gene expression with immune infiltration was analyzed by TIMER algorithm. Results: NCBP1 was significantly upregulated in breast cancer. High expression of NCBP1 correlated with lower overall survival and nomogram model further confirmed that NCBP1 could be a prognostic biomarker in breast cancer. ROC analysis showed that the areas under the ROC curve (AUC) of NCBP1 was 0.731. Additionally, we found that NCBP1 was significantly related to CD8+T cell, Neutrophil, Macrophage and Myeloid dendritic cell. Conclusion: NCBP1 can be used as a diagnosis and prognostic biomarker for breast cancer, which is closely related to tumor immune infiltration.
|
|
Received: 30 August 2022
|
|
|
|
Corresponding Authors:
XUAN Shu. E-mail: woaixuanshu1314@163.com
|
|
|
|
[1] Lei S, Zheng R, Zhang S, et al.Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020[J].Cancer Commun(Lond), 2021, 41(11):1183-1194.
[2] Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021, 71(3):209-249.
[3] Soerjomataram I, Bray F.Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070[J].Nat Rev Clin Oncol, 2021, 18(10):663-672.
[4] Gebhardt A, Habjan M, Benda C, et al.mRNA export through an additional cap-binding complex consisting of NCBP1 and NCBP3[J].Nat Commun, 2015, 6(5):8192-8205.
[5] Dou Y, Barbosa I, Jiang H, et al.NCBP3 positively impacts mRNA biogenesis[J].Nucleic Acids Res, 2020, 48(18):10413-10427.
[6] Zhang H, Wang A, Tan Y, et al.NCBP1 promotes the development of lung adenocarcinoma through up-regulation of CUL4B[J].J Cell Mol Med, 2019, 23(10):6965-6977.
[7] Vivian J, Rao AA, Nothaft FA, et al.Toil enables reproducible, open source, big biomedical data analyses[J].Nat Biotechnol, 2017, 35(4):314-316.
[8] Chin CH, Chen SH, Wu HH, et al.CytoHubba: identifying hub objects and sub-networks from complex interactome[J].BMC Syst Biol, 2014, 8(4):4-11.
[9] Yu G, Wang LG, Han Y, et al.ClusterProfiler: an R package for comparing biological themes among gene clusters[J].OMICS, 2012, 16(5):284-287.
[10] Newman AM, Liu CL, Green MR, et al.Robust enumeration of cell subsets from tissue expression profiles[J].Nat Methods, 2015, 12(5):453-457.
[11] Racle J, de Jonge K, Baumgaertner P, et al. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data[J].Elife, 2017, 6(3):e26476.
[12] Finotello F, Mayer C, Plattner C, et al.Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data[J].Genome Med, 2019, 11(1):34-45.
[13] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J].CA Cancer J Clin, 2017, 67(1):7-30.
[14] Cho H, Rambout X, Gleghorn ML, et al.Transcriptional coactivator PGC-1alpha contains a novel CBP80-binding motif that orchestrates efficient target gene expression[J].Genes Dev, 2018, 32(7-8):555-567.
[15] Safe S, Abbruzzese J, Abdelrahim M, et al.Specificity protein transcription factors and cancer: Opportunities for drug development[J].Cancer Prev Res(Phila), 2018, 11(7):371-382.
[16] Shen L, Pili R.Posttranscription regulation of prostate cancer growth[J].Cancer J, 2008, 14(1):46-53.
[17] Dou Y, Barbosa I, Jiang H, et al.NCBP3 positively impacts mRNA biogenesis[J].Nucleic Acids Res, 2020, 48(18):10413-10427.
[18] Kisaki CY, Arcos S, Montoni F, et al.Bothrops jararaca snake venom modulates key cancer-related proteins in breast tumor cell lines[J].Toxins(Basel), 2021, 13(8):135-149.
[19] Rambout X, Maquat LE.NCBP3: A multifaceted adaptive regulator of gene expression[J].Trends Biochem Sci, 2021, 46(2):87-96.
[20] Gonatopoulos-Pournatzis T, Cowling VH.Cap-binding complex(CBC)[J].Biochem J, 2014, 457(2):231-242.
[21] Verma R, Hanby AM, Horgan K, et al.Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer[J].Breast Cancer Res Treat, 2020, 183(1):49-59.
[22] Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J].Lancet Oncol, 2018, 19(1):40-50.
[23] Pruneri G, Vingiani A, Denkert C.Tumor infiltrating lymphocytes in early breast cancer[J].Breast, 2018, 37(10):207-214.
[24] Schnellhardt S, Erber R, Buttner-Herold M, et al.Tumour-infiltrating inflammatory cells in early breast cancer: An underrated prognostic and predictive factor[J].Int J Mol Sci, 2020, 21(21):123-136.
[25] Picard E, Verschoor CP, Ma GW, et al.Relationships between immune landscapes, genetic subtypes and responses to immunotherapy in colorectal cancer[J].Front Immunol, 2020, 11(9):369-388.
[26] Wang S, Xiong Y, Zhang Q, et al.Clinical significance and immunogenomic landscape analyses of the immune cell signature based prognostic model for patients with breast cancer[J].Brief Bioinform, 2021, 22(4):71-85.
[27] Xiao Y, Ma D, Zhao S, et al.Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer[J].Clin Cancer Res, 2019, 25(16):5002-5014.
[28] Sui S, An X, Xu C, et al.An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer[J].Theranostics, 2020, 10(26):11938-11949. |
|
|
|
